ACTU · CIK 1652935
What Actuate Therapeutics, Inc. told the SEC could break it.
Everything Actuate disclosed rests on a single unapproved drug candidate, elraglusib. It is clinical-stage and pre-revenue, with a $154.6 million accumulated deficit at the end of 2025 and a need for continued outside financing to keep development going — and its commercialization hinges on lengthy, uncertain FDA approval (it holds Rare Pediatric Disease Designation) plus separate ex-US authorizations and cost-effectiveness reviews. That single-candidate dependence narrows further at the supply chain: the drug substance for elraglusib comes from one China-based manufacturer, bought on a purchase-order basis with no long-term agreement, leaving Actuate exposed to any disruption — including shifts in U.S.-China relations — at that single source.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- clinical-stage, pre-revenue, single drug candidate (elraglusib); $154.6M accumulated deficithigh
Actuate has no approved products and no product revenue, depends entirely on its sole candidate elraglusib, and had a $154.6M accumulated deficit at year-end 2025 — needing continued financing (e.g. a B. Riley equity facility) to advance development.
“We have incurred and expect to continue to incur significant costs in the development of our sole drug candidate, elraglusib.”
SEC filing →As of 2026
Sole-source dependency
- single China-based manufacturer for elraglusib drug substance (no long-term supply agreement)high
Actuate relies on a single company in China to manufacture the drug substance (DS) for its sole product candidate elraglusib, obtains supplies on a purchase-order basis with no long-term agreement, and may need single suppliers for other materials/services — a sharp single-source/sole-source risk.
“We currently have a sole source manufacturer for the DS for elraglusib, and, while we believe that a suitable alternative vendor would be available if needed, some of these materials may at times only be available fro”
SEC filing →As of 2026
Regulatory & policy
- FDA approval (RPDD) and ex-US approval/reimbursement (Health Canada, EU/UK NICE HTA)medium
Actuate's commercialization depends on lengthy, uncertain FDA approval of elraglusib (it holds Rare Pediatric Disease Designation) and on ex-US authorities (Health Canada, EU/UK with NICE HTA cost-effectiveness review) plus drug-pricing/reimbursement regimes.
“In the UK, NICE is the body in England and Wales, which conducts HTAs and issues guidance on whether a product is considered to be “cost-effective” and therefore recommended for use and reimbursement under the national health service.”
SEC filing →As of 2026
Geographic concentration
- China dependence for drug substance and potential clinical-trial vendors (US-China geopolitical risk)low
Actuate's drug substance is made by a single China-based company (with drug-product finishing in the US) and it may rely on China-located or Chinese-owned vendors for trial support; US-China geopolitical shifts could impair DS access, raise costs, and delay trials and approval.
“It is unknown how current or future geopolitical relationships with China may affect our ability to obtain DS, increase our costs, delay clinical trials and potential regulatory approval, and adversely impact our financial condition.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch